Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by yorgosGKon Apr 25, 2018 3:23pm

248 Views

Post# 27939988

Great for the 4 CBD drug companies

Great for the four getting FDA approved drugs.

KALY is #2 in line after GW On June 17th.

Then the only remaining 2 players Nasdaq: ZYNE & Nasdaq: CRBP (in early Phase 2)

And did I mention KALY is the only one giving an insurmountable ROI.

Read about the latest bill to pass the house unanimously here

Bullboard Posts

Canadian psychedelic stock to supply MDMA to Yale